Cleared Traditional

SERUM CHOLINESTERASE REAGENT SET (K833062) - FDA 510(k) Clearance

Class I Chemistry device.

K833062 · Sterling Biochemical, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1983
Decision
78d
Days
Class 1
Risk

K833062 is an FDA 510(k) clearance for the SERUM CHOLINESTERASE REAGENT SET. Classified as Acetylcholine Chloride, Specific Reagent For Pseudo Cholinesterase (product code DLI), Class I - General Controls.

Submitted by Sterling Biochemical, Inc. (Mchenry, US). The FDA issued a Cleared decision on November 25, 1983 after a review of 78 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.3240 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Sterling Biochemical, Inc. devices

Submission Details

510(k) Number K833062 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 08, 1983
Decision Date November 25, 1983
Days to Decision 78 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
10d faster than avg
Panel avg: 88d · This submission: 78d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code DLI Acetylcholine Chloride, Specific Reagent For Pseudo Cholinesterase
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.3240
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.